Open AccessActive Smoking May Negatively Affect Response Rate, Progression‐Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Author(s) -
Keizman Daniel,
Gottfried Maya,
IshShalom Maya,
Maimon Natalie,
Peer Avivit,
Neumann Avivit,
Hammers Hans,
Eisenberger Mario A.,
Sinibaldi Victoria,
Pili Roberto,
Hayat Henry,
Kovel Svetlana,
Sella Avishay,
Boursi Ben,
Weitzen Rony,
Mermershtain Wilmosh,
Rouvinov Keren,
Berger Raanan,
Carducci Michael A.
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0335
Subject(s) - medicine , sunitinib , hazard ratio , renal cell carcinoma , oncology , proportional hazards model , progression free survival , body mass index , gastroenterology , diabetes mellitus , confidence interval , endocrinology , chemotherapy
Learning ObjectivesDescribe the association between risk factors for renal cell carcinoma and the outcome of sunitinib treatment for metastatic disease. Explain the impact of active smoking on the outcome of sunitinib‐treated metastatic renal cell carcinoma. Discuss obesity, hypertension, and diabetes in relation to the outcome of sunitinib‐treated metastatic renal cell carcinoma.